Registration Options

Activity Dates: 01/12/2024 - 12/31/2025

Target Audience

The Psychiatric Pharmacotherapy Review Book is designed for three primary audiences:

  1. It serves as a preparatory book for pharmacists preparing to sit for the BCPP examination.
  2. It offers a review of current evidence-based pharmacotherapy for psychiatric and neurologic conditions for BCPP certified pharmacists seeking BCPP recertification credit (purchase here).
  3. It serves as an educational tool for other healthcare providers on current evidence-based pharmacotherapy for psychiatric and neurologic conditions.

NOTE: The Psychiatric Pharmacotherapy Review Book is a two-year product released at the start of even years (2024, 2026...).

Session Summary

The Psychiatric Pharmacotherapy Review Book is designed for use by individuals preparing to sit for the Board Certified Psychiatric Pharmacist (BCPP) examination. AAPP surveys show that at least 90% of successful BCPP candidates purchase the Review Book as their primary study tool. One hundred percent of survey respondents indicate that the Review Book was their primary study resource and a key tool to their certification success.

The Book Contains:

  • Comprehensive outlines, written as individual chapters, of the most common psychiatric and neurologic conditions tested for in the BCPP exam.
  • Consistently formatted chapters that include objectives, thorough content, comprehensive reference listings, and self-assessment questions with answer justifications.
  • An e-book version of the book hosted VitalSource Bookshelf, a leading e-textbook solution. This e-book version allows you to take electronic notes as well as download the book to your desktop or mobile device for off line access. The pricing above reflects the cost for the digital version of the book. There is an additional fee for shipping a hard copy of the book and this option can be selected upon check-out.

To maintain its strict, independent standards for certification, BPS does NOT develop, endorse, or support review information, preparatory courses, or study guides.

Faculty Information

Charles F. Caley, PharmD, BCPP
Clinical Professor | Chair
Western New England University
Springfield, MA
No Relevant Financial Relationships to Disclose
 
Ryan M. Carnahan, PharmD, BCPP, MS
Associate Professor
University of Iowa, College of Public Health, Epidemiology
Iowa City, IA
No Relevant Financial Relationships to Disclose
 
Jeremy Daniel, PharmD, BCPP, BCPS
Associate Professor of Pharmacy Practice
South Dakota State University College of Pharmacy and Allied Health Professions
Sioux Falls, SD
No Relevant Financial Relationships to Disclose
 
Sarah E. Grady, PharmD, BCPP, BCPS
Clinical Professor
Drake University
Des Moines, IA
No Relevant Financial Relationships to Disclose
My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices.
 
Robin N. Hieber, PharmD, BCPP
Clinical Pharmacy Specialist - Mental Health & Clinical Pharmacy Lead
VISN 23 Clinical Resource Hub
IL
No Relevant Financial Relationships to Disclose
 
Megan Maroney, PharmD, BCPP
Clinical Associate Professor
Ernest Mario School of Pharmacy at Rutgers, the State University of New Jersey
Long Branch, NJ
Consultant: Novus Medical Education, Pharmacy Times-Health Systems Edition
Speaker’s Bureau: Otsuka
Other Financial Support: Advisory Board-Sunovion, Boehrenger Ingelheim; Honoraria-Pharmacy Times, American College of Clinical Pharmacy
My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: amphetamines, cabergoline, carbidopa/levodopa, clomipramine, clonidine, corticosteroids, diphenhydramine, gabapentin, melatonin, methadone, methylphenidate, mirtazapine, oxycodone, pregabalin, quetiapine, selegiline, trazodone, valerian, venlafaxine
 
Lindsey N. Miller, PharmD, BCPP
Clinical Pharmacist and Associate Professor
Lipscomb University and Vanderbilt Psychiatric Hospital
Nashville, TN
No Relevant Financial Relationships to Disclose
My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: Nearly all medications in this section are off-label
 
Sandra Mitchell, PharmD, BCPP
Clinical Pharmacy Specialist - Psychiatry
VCU Health Systems
Richmond, VA
Consultant: Wolters-kluwer (Lexi-comp)
My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: ADHD – bupropion, modafinil; ASD – haloperidol, fluphenazine, chlorpromazine, divalproex, N-acetylcysteine, amantadine, melatonin, omega-3 fatty acids, probiotics, zinc; Tics – risperidone, tiapride, sulpride, clonidine, guanfacine, olanzapine, quetiapine, ziprasidone, fluphenazine, botulinum toxin, metoclopramide, baclofen, levetiracetam, IVIG, NAC, nicotine, riluzole, d-serine, ondansetron, pramipexole, methylphenidate, desipramine; ODD/CD – antipsychotics, stimulants; Klinefelter’s – ZYN002
 
Carol A. Ott, PharmD, MPH, BCPP
Clinical Professor of Pharmacy Practice
Purdue University/Eskenazi Health
Indianapolis, IN
External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Project ECHO - Indiana University - Opioid Use Disorders - Expert Panelist, Tippecanoe County (Indiana) Public Defender's Office - case consultation, Psychopharmacology Consultation Team - Indiana University - Department of Child Services, Wolters-Kluwer/Lexi-Comp
Educational grants: SAMHSA
Non-Financial Interests: Indiana Medicaid Drug Utilization Review (DUR) Board, Indiana Medicaid Mental Health Quality Advisory Committee (MHQAC), NAMI West Central Indiana
 
Chris Paxos, BCGP, BCPP, BCPS
Professor, Pharmacy Practice
Northeast Ohio Medical University
Rootstown, OH
No Relevant Financial Relationships to Disclose
 
Kimberly B. Tallian, PharmD, BCPP, FASHP, FCCP*
Advanced Practice Pharmacist - Psychiatry
Scripps Mercy Hospital, San Diego, CA
San Diego, CA
Speaker's Bureau: San Diego Regional Center & San Diego Epilepsy Foundation
 
 * This 2024-2025 Psychiatric Pharmacotherapy Review product is dedicated to the memory of Kim Tallian, PharmD, APH, BCPP, FASHP, FCCP, FCSHP, who passed away in January of 2023. Dr. Tallian has authored the Neurologic Disorders chapter for this product for the past decade, including this edition of the product. We are thankful to her for her lasting contributions to this product and AAPP.
 
Michele D. Thomas, PharmD, BCPP
Director of Pharmacy
Springfield Hospital Center
Sykesville, MD
No Relevant Financial Relationships to Disclose
 
Erika Titus-Lay, PharmD, BCPP, BCPS
Clinical Pharmacist
Kaiser Permanente
Sacramento, CA
Grant Support: ASHP Pharmacy Leadership Scholars Research Grant for $10,000
 
Andrew M. Williams, PharmD, BCPP
Supervising Clinical Pharmacist, Behavioral Health Pharmacies
Riverside University Health System
Riverside, CA
No Relevant Financial Relationships to Disclose
My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: Antipsychotics for Behavioral and Psychiatric Symptoms of Dementia

Learning Objectives

Topic

 

 

Continuing Education Credit and Disclosures

View AAPP's Privacy Policy

AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.

Questions? Contact AAPP.